Welcome to our dedicated page for Lemaitre Vasculr news (Ticker: LMAT), a resource for investors and traders seeking the latest updates and insights on Lemaitre Vasculr stock.
LeMaitre Vascular, Inc. provides devices, implants, and services for the treatment of peripheral vascular disease. The company develops, manufactures, and markets disposable and implantable vascular devices for vascular surgeons, with products used in arteries and veins.
Recurring LMAT news includes quarterly financial results, guidance, dividend declarations, and management presentations at healthcare investor conferences. Company updates also discuss product categories such as Artegraft, grafts, valvulotomes, and carotid shunts, along with sales activity across the Americas, EMEA, and Asia Pacific.
LeMaitre (Nasdaq:LMAT) reported Q2 2021 results with sales of $40.7 million, a 64% increase year-over-year. Operating income rose by 128% to $11.1 million, yielding an operating margin of 27%. Net income jumped 137% to $8.3 million, with earnings per diluted share at $0.40, a 131% increase. Despite a gross margin decline to 65.8%, driven by product mix and manufacturing inefficiencies, the company completed a $54.5 million follow-on stock offering. Q3 2021 guidance suggests sales between $38.3 million and $40.3 million.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) will announce its Q2 2021 financial results on July 29, 2021, after market close. A conference call is set for the same day at 5:00 PM ET to discuss the results and company outlook. The call can be accessed by dialing 844-239-5284 or through a webcast at the company’s investor relations page. LeMaitre specializes in devices for peripheral vascular disease, serving over 200 million worldwide.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) has priced a public offering of 1,000,000 shares at $54.50 each, expecting gross proceeds of approximately $54.5 million. Closing is anticipated around July 16, 2021. Underwriters have an option to buy 150,000 additional shares. Proceeds will be used to repay senior secured credit facility borrowings, for corporate purposes, and potential acquisitions. The offering follows SEC registration and is conducted via a prospectus. Jefferies and Stifel are the joint book-running managers for this offering.
LeMaitre Vascular (Nasdaq:LMAT) has begun an underwritten public offering of its common stock, with an option for underwriters to purchase an additional 15% of shares. The proceeds will be used to fully repay borrowings under its senior secured credit facility and for corporate purposes, including working capital and potential acquisitions. Jefferies LLC and Stifel are the joint book-running managers. The offering is subject to market conditions, and details will be available in the SEC filings.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced preliminary Q2 2021 results, reporting net sales of $40.7 million, a 64% increase compared to Q2 2020, with organic growth of 35%. Operating income reached approximately $10.9 million to $11.3 million, up 128%. The gross margin declined to 65.5%-66.1%, impacted by inventory write-downs and manufacturing inefficiencies. Geographic sales growth was strong across all regions, especially in the Americas (+83%). Cash and cash equivalents stood at $21.8 million, while debt decreased by $9 million to $23 million.
LeMaitre Vascular (Nasdaq:LMAT) announced that President David Roberts will present at the Goldman Sachs 42nd Annual Virtual Global Healthcare Conference on June 10, 2021, at 5:30 PM ET. The company specializes in devices, implants, and services for peripheral vascular disease, affecting over 200 million people globally. LeMaitre develops and markets vascular devices tailored to vascular surgeons.
LeMaitre (Nasdaq:LMAT) announced the receipt of CE marks for five vascular products after a prior lapse due to a change in notified bodies. The newly certified products include XenoSure Biologic Patches, AlboGraft Polyester Vascular Grafts, and various Carotid Shunts, with expiration dates extending to 2024. Notably, the XenoSure's indications no longer cover neuro or cardiac applications. Andrew Hodgkinson highlighted that despite some product line losses totaling 3% of EMEA sales, customer supplies remained largely uninterrupted due to existing inventory.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) will have its CFO, JJ Pellegrino, present at the Jefferies Virtual Healthcare Conference on June 4, 2021, at 1:30 PM EDT. The company specializes in devices and services for peripheral vascular disease, which affects over 200 million individuals globally. LeMaitre develops and markets both disposable and implantable vascular devices aimed at vascular surgeons. For more details, visit www.lemaitre.com.
LeMaitre (Nasdaq:LMAT) reported Q1 2021 results showing sales of $35.9 million, a 17% increase year-over-year, despite a 5% organic decline. Net income reached $5.9 million, up 87%, with earnings per share of $0.28, also an 83% increase. Sales in the Americas and Asia/Pac grew significantly, while Europe/Middle East/Africa experienced a decline. The company declared a quarterly dividend of $0.11 per share, to be paid on June 3, 2021. For Q2 2021, LeMaitre projects sales between $37 million and $40 million, with a gross margin of 66.7%. Their share repurchase program has been authorized for up to $15 million.
LeMaitre Vascular announced its participation in two upcoming investor conferences in May 2021. David Roberts, President, will present at the 7th Annual Truist Securities Life Sciences Summit on May 4, 2021. He will also be featured at the UBS Global Healthcare Virtual Conference on May 26, 2021, at 9:00 AM EDT. LeMaitre specializes in devices and services for treating peripheral vascular disease, impacting over 200 million people globally. The firm develops vascular devices tailored for vascular surgeons. More information is available at lemaitre.com.